These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 31921686)

  • 1. Severe Immune-Related Pneumonitis With PD-1 Inhibitor After Progression on Previous PD-L1 Inhibitor in Small Cell Lung Cancer: A Case Report and Review of the Literature.
    Liang X; Guan Y; Zhang B; Liang J; Wang B; Li Y; Wang J
    Front Oncol; 2019; 9():1437. PubMed ID: 31921686
    [No Abstract]   [Full Text] [Related]  

  • 2. [Immune-related pneumonitis caused by programmed death-1 inhibitor Pembrolizumab: a case report and literature review].
    Chen YL; Zhao J; Jia R; Wang HY; Zheng J; Bai CQ; Wang MZ; Xu JM
    Zhonghua Jie He He Hu Xi Za Zhi; 2017 Oct; 40(10):736-743. PubMed ID: 29050127
    [No Abstract]   [Full Text] [Related]  

  • 3. Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis.
    Sun X; Roudi R; Dai T; Chen S; Fan B; Li H; Zhou Y; Zhou M; Zhu B; Yin C; Li B; Li X
    BMC Cancer; 2019 Jun; 19(1):558. PubMed ID: 31182061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of rare but severe immune related adverse effects in PD-1 and PD-L1 inhibitors in non-small cell lung cancer: a meta-analysis.
    Hu YB; Zhang Q; Li HJ; Michot JM; Liu HB; Zhan P; Lv TF; Song Y;
    Transl Lung Cancer Res; 2017 Dec; 6(Suppl 1):S8-S20. PubMed ID: 29299404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune Thrombocytopenia Induced by Immune Checkpoint Inhibitors in Solid Cancer: Case Report and Literature Review.
    Liu X; Liang X; Liang J; Li Y; Wang J
    Front Oncol; 2020; 10():530478. PubMed ID: 33365266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Programmed cell death 1 (PD-1)/PD-ligand 1(PD-L1) inhibitors-related pneumonitis in patients with advanced non-small cell lung cancer.
    Sun Y; Shao C; Li S; Xu Y; Xu K; Zhang Y; Huang H; Wang M; Xu Z
    Asia Pac J Clin Oncol; 2020 Dec; 16(6):299-304. PubMed ID: 32757454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Pneumonitis Rates and Severity in Patients With Lung Cancer Treated by Immunotherapy, Radiotherapy, and Immunoradiotherapy.
    Aiad M; Fresco K; Prenatt Z; Tahir A; Ramos-Feliciano K; Stoltzfus J; Harmouch F; Wilson M
    Cureus; 2022 Jun; 14(6):e25665. PubMed ID: 35677739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of immune-related pneumonitis with the efficacy of PD-1/PD-L1 inhibitors in non-small cell lung cancer.
    Cui P; Huang D; Wu Z; Tao H; Zhang S; Ma J; Liu Z; Wang J; Huang Z; Chen S; Zheng X; Hu Y
    Ther Adv Med Oncol; 2020; 12():1758835920922033. PubMed ID: 32426052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pneumonitis From Anti-PD-1/ PD-L1 Therapy.
    Balaji A; Verde F; Suresh K; Naidoo J
    Oncology (Williston Park); 2017 Oct; 31(10):739-46, 754. PubMed ID: 29083466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Trials.
    Khunger M; Rakshit S; Pasupuleti V; Hernandez AV; Mazzone P; Stevenson J; Pennell NA; Velcheti V
    Chest; 2017 Aug; 152(2):271-281. PubMed ID: 28499515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of Pneumonitis and Pneumonia Associated With Immune Checkpoint Inhibitors for Solid Tumors: A Systematic Review and Meta-Analysis.
    Su Q; Zhu EC; Wu JB; Li T; Hou YL; Wang DY; Gao ZH
    Front Immunol; 2019; 10():108. PubMed ID: 30778352
    [No Abstract]   [Full Text] [Related]  

  • 12. The Relative Risk and Incidence of Immune Checkpoint Inhibitors Related Pneumonitis in Patients With Advanced Cancer: A Meta-Analysis.
    Ma K; Lu Y; Jiang S; Tang J; Li X; Zhang Y
    Front Pharmacol; 2018; 9():1430. PubMed ID: 30618738
    [No Abstract]   [Full Text] [Related]  

  • 13. HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis.
    Correale P; Saladino RE; Giannarelli D; Sergi A; Mazzei MA; Bianco G; Giannicola R; Iuliano E; Forte IM; Calandruccio ND; Falzea AC; Strangio A; Nardone V; Pastina P; Tini P; Luce A; Caraglia M; Caracciolo D; Mutti L; Tassone P; Pirtoli L; Giordano A; Tagliaferri P
    Cells; 2020 Aug; 9(9):. PubMed ID: 32854442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiation recall pneumonitis induced by PD-1/PD-L1 blockades: mechanisms and therapeutic implications.
    Teng F; Li M; Yu J
    BMC Med; 2020 Sep; 18(1):275. PubMed ID: 32943072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of mycophenolate-resistant immune-related organizing pneumonia with infliximab.
    Ortega Sanchez G; Jahn K; Savic S; Zippelius A; Läubli H
    J Immunother Cancer; 2018 Sep; 6(1):85. PubMed ID: 30176946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and tolerability of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer: a meta-analysis of randomized controlled trials.
    Luo W; Wang Z; Tian P; Li W
    J Cancer Res Clin Oncol; 2018 Oct; 144(10):1851-1859. PubMed ID: 30019319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence, risk factors, and CT characteristics of radiation recall pneumonitis induced by immune checkpoint inhibitor in lung cancer.
    Cousin F; Desir C; Ben Mustapha S; Mievis C; Coucke P; Hustinx R
    Radiother Oncol; 2021 Apr; 157():47-55. PubMed ID: 33453313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two severe adverse events triggered by an anti-PD-1 immune checkpoint inhibitor in an advanced lung cancer patient: a case report and review of the literature.
    Bao Z; Sun X; Chen W; Tang W; Gao B; Xiang Y
    Ann Transl Med; 2021 Aug; 9(16):1358. PubMed ID: 34532495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Severe pulmonary toxicity from immune checkpoint inhibitor treated successfully with intravenous immunoglobulin: Case report and review of the literature.
    Petri CR; Patell R; Batalini F; Rangachari D; Hallowell RW
    Respir Med Case Rep; 2019; 27():100834. PubMed ID: 31008047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and Tolerability of PD-1/PD-L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis.
    Nishijima TF; Shachar SS; Nyrop KA; Muss HB
    Oncologist; 2017 Apr; 22(4):470-479. PubMed ID: 28275115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.